Taiko Pharmaceutical Co (TSE:4574) Total Stockholders Equity: 円8,425 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4574 Taiko Pharmaceutical Co Ltd TSE:4574
64 GF Score
Price 円257.00
GF Value 円321.53
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Taiko Pharmaceutical Co Total Stockholders Equity?

Taiko Pharmaceutical Co TSE:4574 -0.39% 64 Total Stockholders Equity is 円8,425 Mil as of Jun. 2026. GuruFocus rates TSE:4574 with a GF Score™ of 64/100 and a GF Value™ of 円321.53 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Taiko Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Jun. 2026 was 円8,425 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Taiko Pharmaceutical Co's Book Value per Share for the quarter that ended in Jun. 2026 was 円167.47. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Taiko Pharmaceutical Co's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.02.

Taiko Pharmaceutical Co  (TSE:4574) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Taiko Pharmaceutical Co's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(8425-0)/50.308081
=167.47

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Taiko Pharmaceutical Co's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(119 + 53) / 8425
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiko Pharmaceutical Co Total Stockholders Equity Related Terms

Taiko Pharmaceutical Co Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Taiko Pharmaceutical Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiko Pharmaceutical Co Total Stockholders Equity Chart

Taiko Pharmaceutical Co Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,807.00 8,044.00 6,739.00 7,964.00 8,518.00

Taiko Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,948.00 8,236.00 8,518.00 8,264.00 8,425.00
TSE:4574
64GF Score
Taiko Pharmaceutical Co Ltd TSE:4574
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of 円8,425 Mil mean?
Taiko Pharmaceutical Co (TSE:4574) has a Total Stockholders Equity of 円8,425 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Taiko Pharmaceutical Co and its competitors.
Is Taiko Pharmaceutical Co's Total Stockholders Equity too high?
Taiko Pharmaceutical Co's current Total Stockholders Equity is 円8,425 Mil. Overall, Taiko Pharmaceutical Co has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Taiko Pharmaceutical Co's Total Stockholders Equity compare to ZTS?
Taiko Pharmaceutical Co's Total Stockholders Equity of 円8,425 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Taiko Pharmaceutical Co and its competitors. Taiko Pharmaceutical Co's current Total Stockholders Equity is 円8,425 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiko Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co (TSE:4574) is currently considered Modestly Undervalued. The stock's GF Value™ is 円321.53, compared to a current price of 円257.00 — trading 20.1% below its estimated fair value. The current Total Stockholders Equity is 円8,425 Mil. Taiko Pharmaceutical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Taiko Pharmaceutical Co (TSE:4574), the current Total Stockholders Equity is 円8,425 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiko Pharmaceutical Co (TSE:4574) Overvalued in 2026?

Based on GuruFocus' analysis, Taiko Pharmaceutical Co stock appears to be undervalued. The current stock price of 円257.00 is trading 20.1% below its estimated GF Value™ of 円321.53. GuruFocus considers Taiko Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4574:

  • Total Stockholders Equity: 円8,425 Mil
  • GF Value™: 円321.53 vs. price of 円257.00 (20.1% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the TSE:4574 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiko Pharmaceutical Co Business Description

Address 1-4-1 Nishihonmachi, 16th Floor, ORIX Honmachi Building, Nishi-ku, Osaka, JPN, 564-0032
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.
64GF Score

Get the complete analysis for TSE:4574

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円257.00
Price
円321.53
GF Value